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Background: Bivalirudin and vascular closure devices reduce bleeding complications in percutaneous coronary intervention (PCI) patients. We 
studied the comparative effectiveness and frequency of use of both in PCI patients with diverse bleeding risk levels.
Methods: Analysis of patients from the National Cardiovascular Data Registry® CathPCI registry® reported between 2004-2008. Major bleeding 
events required transfusion, prolonged hospital stay, and/or hemoglobin drop >3 g/dL. The validated NCDR bleeding risk model was used to stratify 
patients into low (3%) categories for peri-PCI bleeding.
Results: There were 1.5 million PCI procedures evaluated. Major bleeding occurred in 30,429 (2%) patients. The Figure presents observed bleeding 
events and number needed to treat to prevent 1 bleeding event by use of bivalirudin, vascular closure devices, both, or neither for the total group 
and stratified by subgroup of bleeding risk. The combination of bivalirudin and closure devices was associated with the lowest rate of bleeding 
in each group. High risk patients were more likely to receive no therapy than low risk patients (40% vs 31%, P<0.001) and less likely to receive 
combination therapy (14% vs 21%, P<0.001).
Conclusions: Combined use of bivalirudin and closure devices is associated with reduced bleeding, with the greatest benefit observed in high risk 
patients. Use of these therapies is paradoxically more common in low risk patients.
